US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.



Biosimilars: The Evolution of a New Industry (Review)

KEY POINTS The global oncology mAb market is expected to reach around $45 billion by the end of this decade. ...


Liquid Biopsy: The Golden Cancer Diagnostic Test (an Industrial Review)

KEY POINTS The liquid biopsy market is forecasted to grow at a CAGR of 20.6 percent to reach over $3 ...


World’s 10 Top-Selling Orphan Drugs 2018

KEY POINTS Here are the 10 top-selling orphan drugs in terms of their worldwide sales in the previous financial year. ...


[QUIZ] Healthcare Industry Knowledge Assessment

Healthcare Industry Knowledge Assessment How well do you know the healthcare industry? Take this assessment to identify your knowledge of ...

Most Popular


7 New Ideas to Start a Healthcare Business in India (2018)

Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...


Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply